The Duke Gene Therapy Resource Core (GTRC) is committed to providing scalable production and analytics for platform AAV & RNA technologies to enable pre-clinical gene therapy development.
Our Services
- Extensive portfolio of novel engineered AAV capsids for gene transfer applications across species
- Versatile portfolio of engineered RNA platform cargos including circRNA, shRNA, guide RNAs (for DNA/RNA editing)
- Custom design of recombinant adeno-associated virus (rAAV) vectors
- Research grade suspension cell manufacturing of rAAV vectors (5L- 50L scale)
- State-of-the-art analytics for research-grade AAV preparations
Engineered AAV Capsid Portfolio
Our AAV process & analytics capabilities
Grants and Collaborators supported by Duke GTRC
- NIH funded R01 and U01 projects
- Duke Ex Vivo Organ Laboratory, Department of Surgery
- Duke Center for Applied Genome Technologies
- Department of Defense funded projects (with Duke Molecular Genetics & Microbiology and University of Chicago)
- Duke Pediatrics (Y.T. and Alice Chen Pediatric Genetics and Genomics Research Center)
- Duke Regeneration Center
- California National Primate Research Center, UC Davis
- Parker Institute for Immunotherapy, Gladstone Institutes, UC San Francisco
- Center for Cerebrovascular Research, UC San Francisco
- Multiple Biotech Industry Partners
Click below for publications supported by our platform technologies and the Duke GTRC!
Affiliated with the Asokan Lab
